NK cell development and function - Plasticity and redundancy unleashed

Seminars in Immunology

Volumn 26, Issue 2, 2014, Pages 114-126

  Cichocki, Frank ^a   Sitnicka, Ewa ^b   Bryceson, Yenan T ^c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cytokine production; Cytotoxicity; Natural killer cells; Primary immunodeficiency; Single nucleotide polymorphisms; Transcription factors

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR NFIL3; CD34 ANTIGEN; CD57 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 22; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; L SELECTIN; LONG UNTRANSLATED RNA; MICRORNA 155; MICRORNA 29; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

3' UNTRANSLATED REGION; ACTIN FILAMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BONE MARROW; CELL FATE; CELL HOMING; CELL LINEAGE; CELL MATURATION; COMMON LYMPHOID PROGENITOR; COMMON MYELOID PROGENITOR; CYTOKINE PRODUCTION; CYTOTOXIC LYMPHOCYTE; DECIDUA; DOWN REGULATION; ENDOPLASMIC RETICULUM; FIRST TRIMESTER PREGNANCY; GENETIC REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPH NODE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOID PROGENITOR CELL; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NEGATIVE FEEDBACK; NONHUMAN; PHENOTYPIC PLASTICITY; PLACENTA CIRCULATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TROPHOBLAST; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; IMMUNITY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; IMMUNITY; KILLER CELLS, NATURAL;

EID: 84897964683     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.02.003     Document Type: Review

References (222)

1. Kiessling R., Klein E., Wigzell H. Natural killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-120.
2. Herberman R.B., Nunn M.E., Holden H.T., Lavrin D.H. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 1975, 16:230-240.
3. Yu J., Freud A.G., Caligiuri M.A. Location and cellular stages of natural killer cell development. Trends Immunol 2013, 34:573-580.
4. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat Immunol 2008, 9:503-510.
5. Flodstrom-Tullberg M., Bryceson Y.T., Shi F.D., Hoglund P., Ljunggren H.G. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009, 21:634-640.
6. Parham P., Moffett A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol 2013, 13:133-140.
7. Carlsten M., Malmberg K.J., Ljunggren H.G. Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int J Cancer 2009, 124:757-760.
8. Orange J.S. Natural killer cell deficiency. J Allergy Clin Immunol 2013, 132:515-520. [quiz 526].
9. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7:329-330.
10. Koepsell S.A., Miller J.S., McKenna D.H. Natural killer cells: a review of manufacturing and clinical utility. Transfusion 2013, 53:404-410.
11. Lanier L.L., Phillips J.H., Hackett J., Tutt M., Kumar V. Natural killer cells: definition of a cell type rather than a function. J Immunol 1986, 137:2735-2740.
12. Chiang S.C., Theorell J., Entesarian M., Meeths M., Mastafa M., Al-Herz W., et al. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood 2013, 121:1345-1350.
13. Bryceson Y.T., Long E.O. Line of attack: NK cell specificity and integration of signals. Curr Opin Immunol 2008, 20:344-350.
14. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9:495-500.
15. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-200.
16. Fauriat C., Long E.O., Ljunggren H.G., Bryceson Y.T. Regulation of human NK cell cytokine and chemokine production by target cell recognition. Blood 2010, 115:2167-2170.
17. Long E.O. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 2008, 224:70-84.
18. Moretta A., Bottino C., Vitale M., Pende D., Biassoni R., Mingari M.C., et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996, 14:619-620.
19. Yokoyama W.M., Daniels B.F., Seaman W.E., Hunziker R., Margulies D.H., Smith H.R. A family of murine NK cell receptors specific for target cell MHC class I molecules. Semin Immunol 1995, 7:89-101.
20. Ljunggren H.G., Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990, 11:237-240.
21. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-650.
22. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013, 13:145-150.
23. Hirahara K., Poholek A., Vahedi G., Laurence A., Kanno Y., Milner J.D., et al. Mechanisms underlying helper T-cell plasticity: implications for immune-mediated disease. J Allergy Clin Immunol 2013, 131:1276-1280.
24. Bezman N.A., Kim C.C., Sun J.C., Min-Oo G., Hendricks D.W., Kamimura Y., et al. Molecular definition of the identity and activation of natural killer cells. Nat Immunol 2012, 13:1000-1010.
25. Sun J.C., Lopez-Verges S., Kim C.C., DeRisi J.L., Lanier L.L. NK cells and immune memory. J Immunol 2011, 186:1891-1900.
26. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-110.
27. Adolfsson J., Mansson R., Buza-Vidas N., Hultquist A., Liuba K., Jensen C.T., et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005, 121:295-300.
28. Haller O., Wigzell H. Suppression of natural killer cell activity with radioactive strontium: effector cells are marrow dependent. J Immunol 1977, 118:1503-1510.
29. Vosshenrich C.A., Di Santo J.P. Developmental programming of natural killer and innate lymphoid cells. Curr Opin Immunol 2013, 25:130-140.
30. Luetke-Eversloh M., Killig M., Romagnani C. Signatures of human NK cell development and terminal differentiation. Front Immunol 2013, 4:499.
31. Sitnicka E. Early cellular pathways of mouse natural killer cell development. J Innate Immun 2011, 3:329-330.
32. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8T cell lineages in interleukin 15-deficient mice. J Exp Med 2000, 191:771-780.
33. Suzuki H., Duncan G.S., Takimoto H., Mak T.W. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor beta chain. J Exp Med 1997, 185:499-500.
34. Park S.Y., Saijo K., Takahashi T., Osawa M., Arase H., Hirayama N., et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 1995, 3:771-780.
35. Eckelhart E., Warsch W., Zebedin E., Simma O., Stoiber D., Kolbe T., et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 2011, 117:1565-1570.
36. Fathman J.W., Bhattacharya D., Inlay M.A., Seita J., Karsunky H., Weissman I.L. Identification of the earliest natural killer cell-committed progenitor in murine bone marrow. Blood 2011, 118:5439-5440.
37. Freud A.G., Caligiuri M.A. Human natural killer cell development. Immunol Rev 2006, 214:56-72.
38. Copley M.R., Beer P.A., Eaves C.J. Hematopoietic stem cell heterogeneity takes center stage. Cell Stem Cell 2012, 10:690-700.
39. Grzywacz B., Kataria N., Blazar B.R., Miller J.S., Verneris M.R. Natural killer-cell differentiation by myeloid progenitors. Blood 2011, 117:3548-3550.
40. Mansson R., Zandi S., Welinder E., Tsapogas P., Sakaguchi N., Bryder D., et al. Single-cell analysis of the common lymphoid progenitor compartment reveals functional and molecular heterogeneity. Blood 2010, 115:2601-2610.
41. Hoyler T., Connor C.A., Kiss E.A., Diefenbach A. T-bet and Gata3 in controlling type 1 and type 2 immunity mediated by innate lymphoid cells. Curr Opin Immunol 2013, 25:139-140.
42. Vahedi G., C Poholek A., Hand T.W., Laurence A., Kanno Y., O'Shea J.J., et al. Helper T-cell identity and evolution of differential transcriptomes and epigenomes. Immunol Rev. 2013, 252:24-40.
43. Rosmaraki E.E., Douagi I., Roth C., Colucci F., Cumano A., Di Santo J.P. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 2001, 31:1900-1910.
44. Ramirez K., Chandler K.J., Spaulding C., Zandi S., Sigvardsson M., Graves B.J., et al. Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1. Immunity 2012, 36:921-930.
45. Lee K.N., Kang H.S., Jeon J.H., Kim E.M., Yoon S.R., Song H., et al. VDUP1 is required for the development of natural killer cells. Immunity 2005, 22:195-200.
46. Yokota Y., Mansouri A., Mori S., Sugawara S., Adachi S., Nishikawa S., et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999, 397:702-710.
47. Boos M.D., Yokota Y., Eberl G., Kee B.L. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 2007, 204:1119-1120.
48. Sun X.H., Copeland N.G., Jenkins N.A., Baltimore D. Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol 1991, 11:5603-5610.
49. Colucci F., Samson S.I., DeKoter R.P., Lantz O., Singh H., Di Santo J.P. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001, 97:2625-2630.
50. Lacorazza H.D., Miyazaki Y., Di Cristofano A., Deblasio A., Hedvat C., Zhang J., et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002, 17:437-440.
51. Gascoyne D.M., Long E., Veiga-Fernandes H., de Boer J., Williams O., Seddon B., et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009, 10:1118-1120.
52. Kamizono S., Duncan G.S., Seidel M.G., Morimoto A., Hamada K., Grosveld G., et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med 2009, 206:2977-2980.
53. Aliahmad P., de la Torre B., Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010, 11:945-950.
54. Yokoyama W.M., Kim S., French A.R. The dynamic life of natural killer cells. Annu Rev Immunol 2004, 22:405-410.
55. Walzer T., Blery M., Chaix J., Fuseri N., Chasson L., Robbins S.H., et al. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A 2007, 104:3384-3390.
56. Noda M., Omatsu Y., Sugiyama T., Oishi S., Fujii N., Nagasawa T. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood 2011, 117:451-460.
57. Mayol K., Biajoux V., Marvel J., Balabanian K., Walzer T. Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking. Blood 2011, 118:4863-4870.
58. Gregoire C., Chasson L., Luci C., Tomasello E., Geissmann F., Vivier E., et al. The trafficking of natural killer cells. Immunol Rev 2007, 220:169-170.
59. Freud A.G., Becknell B., Roychowdhury S., Mao H.C., Ferketich A.K., Nuovo G.J., et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005, 22:295-300.
60. Romagnani C., Juelke K., Falco M., Morandi B., D'Agostino A., Costa R., et al. CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 2007, 178:4947-4950.
61. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., et al. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 2007, 179:89-94.
62. Warren C.J., Howell W.M., Bhambhani M., Cawley M.I., Smith J.L. An investigation of T-cell subset phenotype and function in the rheumatoid synovium using in situ hybridization for IL-2 mRNA. Immunology 1991, 72:250-260.
63. Jacobs R., Hintzen G., Kemper A., Beul K., Kempf S., Behrens G., et al. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001, 31:3121-3130.
64. Juelke K., Killig M., Luetke-Eversloh M., Parente E., Gruen J., Morandi B., et al. CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood 2010, 116:1299-1300.
65. Bjorkstrom N.K., Riese P., Heuts F., Andersson S., Fauriat C., Ivarsson M.A., et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010, 116:3853-3860.
66. Samson S.I., Richard O., Tavian M., Ranson T., Vosshenrich C.A., Colucci F., et al. GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity 2003, 19:701-710.
67. Vosshenrich C.A., Garcia-Ojeda M.E., Samson-Villeger S.I., Pasqualetto V., Enault L., Richard-Le Goff O., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 2006, 7:1217-1220.
68. Gordon S.M., Chaix J., Rupp L.J., Wu J., Madera S., Sun J.C., et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012, 36:55-67.
69. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-220.
70. Bezman N.A., Chakraborty T., Bender T., Lanier L.L. miR-150 regulates the development of NK and iNKT cells. J Exp Med 2011, 208:2717-2720.
71. Cichocki F., Felices M., McCullar V., Presnell S.R., Al-Attar A., Lutz C.T., et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. J Immunol 2011, 187:6171-6180.
72. Bezman N.A., Cedars E., Steiner D.F., Blelloch R., Hesslein D.G., Lanier L.L. Distinct requirements of microRNAs in NK cell activation, survival, and function. J Immunol 2010, 185:3835-3840.
73. Zawislak C.L., Beaulieu A.M., Loeb G.B., Karo J., Canner D., Bezman N.A., et al. Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155. Proc Natl Acad Sci U S A 2013, 110:6967-6970.
74. Trotta R., Chen L., Costinean S., Josyula S., Mundy-Bosse B.L., Ciarlariello D., et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013, 121:3126-3130.
75. Sullivan R.P., Fogel L.A., Leong J.W., Schneider S.E., Wong R., Romee R., et al. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. J Immunol 2013, 191:5904-5910.
76. Kim T.D., Lee S.U., Yun S., Sun H.N., Lee S.H., Kim J.W., et al. Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. Blood 2011, 118:5476-5480.
77. Ma F., Xu S., Liu X., Zhang Q., Xu X., Liu M., et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011, 12:861-870.
78. Hu G., Tang Q., Sharma S., Yu F., Escobar T.M., Muljo S.A., et al. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat Immunol 2013, 14:1190-1200.
79. Cichocki F., Hanson R.J., Lenvik T., Pitt M., McCullar V., Li H., et al. The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. Blood 2009, 113:3245-3250.
80. Cichocki F., Lenvik T., Sharma N., Yun G., Anderson S.K., Miller J.S. Cutting edge: KIR antisense transcripts are processed into a 28-base PIWI-like RNA in human NK cells. J Immunol 2010, 185:2009-2010.
81. Wright P.W., Huehn A., Cichocki F., Li H., Sharma N., Dang H., et al. Identification of a KIR antisense lncRNA expressed by progenitor cells. Genes Immun 2013, 14:427-430.
82. Hughes T., Becknell B., Freud A.G., McClory S., Briercheck E., Yu J., et al. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity 2010, 32:803-810.
83. Male V., Hughes T., McClory S., Colucci F., Caligiuri M.A., Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol 2010, 185:3913-3920.
84. Fehniger T.A., Cooper M.A., Nuovo G.J., Cella M., Facchetti F., Colonna M., et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3060.
85. Frey M., Packianathan N.B., Fehniger T.A., Ross M.E., Wang W.C., Stewart C.C., et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 1998, 161:400-410.
86. Luther C., Warner K., Takei F. Unique progenitors in mouse lymph node develop into CD127+ NK cells: thymus-dependent and thymus-independent pathways. Blood 2011, 117:4012-4020.
87. Di Santo J.P. Functionally distinct NK-cell subsets: developmental origins and biological implications. Eur J Immunol 2008, 38:2948-2950.
88. Jenne C.N., Enders A., Rivera R., Watson S.R., Bankovich A.J., Pereira J.P., et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J Exp Med 2009, 206:2469-2470.
89. Moroso V., Famili F., Papazian N., Cupedo T., van der Laan L.J., Kazemier G., et al. NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011, 41:3340-3350.
90. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013, 19:859-860.
91. Paust S., Gill H.S., Wang B.Z., Flynn M.P., Moseman E.A., Senman B., et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010, 11:1127-1130.
92. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002, 2:656-660.
93. Hanna J., Goldman-Wohl D., Hamani Y., Avraham I., Greenfield C., Natanson-Yaron S., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006, 12:1065-1070.
94. Vacca P., Vitale C., Montaldo E., Conte R., Cantoni C., Fulcheri E., et al. CD34+ hematopoietic precursors are present in human decidua and differentiate into natural killer cells upon interaction with stromal cells. Proc Natl Acad Sci U S A 2011, 108:2402-2410.
95. Cerdeira A.S., Rajakumar A., Royle C.M., Lo A., Husain Z., Thadhani R.I., et al. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol 2013, 190:3939-3940.
96. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002, 296:1323-1330.
97. Sun J.C., Madera S., Bezman N.A., Beilke J.N., Kaplan M.H., Lanier L.L. Proinflammatory cytokine signaling required for the generation of natural killer cell memory. J Exp Med 2012, 209:947-950.
98. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-560.
99. Nabekura T., Kanaya M., Shibuya A., Fu G., Gascoigne N.R., Lanier L.L. Costimulatory molecule DNAM-1 is essential for optimal differentiation of memory natural killer cells during mouse cytomegalovirus infection. Immunity 2014.
100. Firth M.A., Madera S., Beaulieu A.M., Gasteiger G., Castillo E.F., Schluns K.S., et al. Nfil3-independent lineage maintenance and antiviral response of natural killer cells. J Exp Med 2013, 210:2981-2990.
101. Guma M., Angulo A., Vilches C., Gomez-Lozano N., Malats N., Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004, 104:3664-3670.
102. Beziat V., Liu L.L., Malmberg J.A., Ivarsson M.A., Sohlberg E., Bjorklund A.T., et al. NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs. Blood 2013, 121:2678-2680.
103. Lopez-Verges S., Milush J.M., Schwartz B.S., Pando M.J., Jarjoura J., York V.A., et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 2011, 108:14725-14730.
104. Foley B., Cooley S., Verneris M.R., Curtsinger J., Luo X., Waller E.K., et al. Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol 2012, 189:5082-5090.
105. Noyola D.E., Fortuny C., Muntasell A., Noguera-Julian A., Munoz-Almagro C., Alarcon A., et al. Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children. Eur J Immunol 2012, 42:3256-3260.
106. Chijioke O., Muller A., Feederle R., Barros M.H., Krieg C., Emmel V., et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection. Cell Rep 2013, 5:1489-1490.
107. Bjorkstrom N.K., Lindgren T., Stoltz M., Fauriat C., Braun M., Evander M., et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011, 208:13-21.
108. Petitdemange C., Becquart P., Wauquier N., Beziat V., Debre P., Leroy E.M., et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 2011, 7:e1002268.
109. Hong H.S., Eberhard J.M., Keudel P., Bollmann B.A., Ballmaier M., Bhatnagar N., et al. HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells. J Virol 2010, 84:1183-1190.
110. Milush J.M., Lopez-Verges S., York V.A., Deeks S.G., Martin J.N., Hecht F.M., et al. CD56negCD16+ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 2013, 10:158.
111. Brunetta E., Fogli M., Varchetta S., Bozzo L., Hudspeth K.L., Marcenaro E., et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. Blood 2009, 114:3822-3830.
112. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-150.
113. Gilmour K.C., Fujii H., Cranston T., Davies E.G., Kinnon C., Gaspar H.B. Defective expression of the interleukin-2/interleukin-15 receptor beta subunit leads to a natural killer cell-deficient form of severe combined immunodeficiency. Blood 2001, 98:877-880.
114. Macchi P., Villa A., Giliani S., Sacco M.G., Frattini A., Porta F., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995, 377:65-68.
115. Russell S.M., Tayebi N., Nakajima H., Riedy M.C., Roberts J.L., Aman M.J., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995, 270:797-800.
116. Kofoed E.M., Hwa V., Little B., Woods K.A., Buckway C.K., Tsubaki J., et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003, 349:1139-1140.
117. Bernasconi A., Marino R., Ribas A., Rossi J., Ciaccio M., Oleastro M., et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 2006, 118:e1584-e1590.
118. Hwa V., Little B., Adiyaman P., Kofoed E.M., Pratt K.L., Ocal G., et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 2005, 90:4260-4270.
119. Hsu A.P., Sampaio E.P., Khan J., Calvo K.R., Lemieux J.E., Patel S.Y., et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011, 118:2653-2660.
120. Dickinson R.E., Griffin H., Bigley V., Reynard L.N., Hussain R., Haniffa M., et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011, 118:2656-2660.
121. Ostergaard P., Simpson M.A., Connell F.C., Steward C.G., Brice G., Woollard W.J., et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011, 43:929-930.
122. Hahn C.N., Chong C.E., Carmichael C.L., Wilkins E.J., Brautigan P.J., Li X.C., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011, 43:1012-1020.
123. Biron C.A., Byron K.S., Sullivan J.L. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989, 320:1731-1740.
124. Mace E.M., Hsu A.P., Monaco-Shawver L., Makedonas G., Rosen J.B., Dropulic L., et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013, 121:2669-2670.
125. Dickinson R.E., Milne P., Jardine L., Zandi S., Swierczek S.I., McGovern N., et al. The evolution of cellular deficiency in GATA2 mutation. Blood 2013.
126. Rodrigues N.P., Janzen V., Forkert R., Dombkowski D.M., Boyd A.S., Orkin S.H., et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 2005, 106:477-480.
127. Gineau L., Cognet C., Kara N., Lach F.P., Dunne J., Veturi U., et al. Partial MCM4 deficiency in patients with growth retardation, adrenal insufficiency, and natural killer cell deficiency. J Clin Invest 2012, 122:821-830.
128. Hughes C.R., Guasti L., Meimaridou E., Chuang C.H., Schimenti J.C., King P.J., et al. MCM4 mutation causes adrenal failure, short stature, and natural killer cell deficiency in humans. J Clin Invest 2012, 122:814-820.
129. Shima N., Alcaraz A., Liachko I., Buske T.R., Andrews C.A., Munroe R.J., et al. A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet 2007, 39:93-98.
130. Ferreira M.A., Mangino M., Brumme C.J., Zhao Z.Z., Medland S.E., Wright M.J., et al. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet 2010, 86:88-92.
131. Orru V., Steri M., Sole G., Sidore C., Virdis F., Dei M., et al. Genetic variants regulating immune cell levels in health and disease. Cell 2013, 155:242-250.
132. Xia Z., Liu Q., Berger C.T., Keenan B.T., Kaliszewska A., Cheney P.C., et al. A 17q12 allele is associated with altered NK cell subsets and function. J Immunol 2012, 188:3315-3320.
133. Berger M., Krebs P., Crozat K., Li X., Croker B.A., Siggs O.M., et al. An Slfn2 mutation causes lymphoid and myeloid immunodeficiency due to loss of immune cell quiescence. Nat Immunol 2010, 11:335-340.
134. Dooms H., Desmedt M., Vancaeneghem S., Rottiers P., Goossens V., Fiers W., et al. Quiescence-inducing and antiapoptotic activities of IL-15 enhance secondary CD4+ T cell responsiveness to antigen. J Immunol 1998, 161:2141-2150.
135. Geserick P., Kaiser F., Klemm U., Kaufmann S.H., Zerrahn J. Modulation of T cell development and activation by novel members of the Schlafen (slfn) gene family harbouring an RNA helicase-like motif. Int Immunol 2004, 16:1535-1540.
136. Rajala H.L., Eldfors S., Kuusanmaki H., van Adrichem A.J., Olson T., Lagstrom S., et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 2013, 121:4541-4550.
137. Koskela H.L., Eldfors S., Ellonen P., van Adrichem A.J., Kuusanmaki H., Andersson E.I., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012, 366:1905-1910.
138. Tassi I., Presti R., Kim S., Yokoyama W.M., Gilfillan S., Colonna M. Phospholipase C-{gamma}2 is a critical signaling mediator for murine NK cell activating receptors. J Immunol 2005, 175:749-750.
139. Caraux A., Kim N., Bell S.E., Zompi S., Ranson T., Lesjean-Pottier S., et al. Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood 2006, 107:994-1000.
140. Bryceson Y.T., Chiang S.C., Darmanin S., Fauriat C., Schlums H., Theorell J., et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011, 3:216-220.
141. Long E.O., Kim H.S., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013, 31:227-230.
142. Colucci F., Schweighoffer E., Tomasello E., Turner M., Ortaldo J.R., Vivier E., et al. Natural cytotoxicity uncoupled from the Syk and ZAP-70 intracellular kinases. Nat Immunol 2002, 3:288-290.
143. Bryceson Y.T., March M.E., Ljunggren H.G., Long E.O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006, 107:159-160.
144. Kim H.S., Long E.O. Complementary phosphorylation sites in the adaptor protein SLP-76 promote synergistic activation of natural killer cells. Sci Signal 2012, 5:ra49.
145. Kim H.S., Das A., Gross C.C., Bryceson Y.T., Long E.O. Synergistic signals for natural cytotoxicity are required to overcome inhibition by c-Cbl ubiquitin ligase. Immunity 2010, 32:175-180.
146. Rajasekaran K., Kumar P., Schuldt K.M., Peterson E.J., Vanhaesebroeck B., Dixit V., et al. Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol 2013, 14:1127-1130.
147. May R.M., Okumura M., Hsu C.J., Bassiri H., Yang E., Rak G., et al. Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function. Blood 2013, 121:3135-3140.
148. Sakai Y., Tanaka Y., Yanagihara T., Watanabe M., Duan X., Terasawa M., et al. The Rac activator DOCK2 regulates natural killer cell-mediated cytotoxicity in mice through the lytic synapse formation. Blood 2013, 122:386-390.
149. Bryceson Y.T., Ljunggren H.G., Long E.O. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009, 114:2657-2660.
150. Brown A.C., Dobbie I.M., Alakoskela J.M., Davis I., Davis D.M. Super-resolution imaging of remodeled synaptic actin reveals different synergies between NK cell receptors and integrins. Blood 2012, 120:3729-3730.
151. Thomas L.M., Peterson M.E., Long E.O. Cutting edge: NK cell licensing modulates adhesion to target cells. J Immunol 2013, 191:3981-3990.
152. Kohl S., Loo L.S., Schmalstieg F.S., Anderson D.C. The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150,95 in humans is associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J Immunol 1986, 137:1688-1690.
153. Lau Y.L., Low L.C., Jones B.M., Lawton J.W. Defective neutrophil and lymphocyte function in leucocyte adhesion deficiency. Clin Exp Immunol 1991, 85:202-210.
154. Castriconi R., Dondero A., Cantoni C., Della Chiesa M., Prato C., Nanni M., et al. Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood 2007, 109:4873-4880.
155. Takeuchi T., Nakagawa T., Ikemoto T., Sasaki M., Makino S., Shimizu A., et al. A novel mutation in the FcgammaRIIIA gene (CD16) results in active natural killer cells lacking CD16. Autoimmunity 1999, 31:265-270.
156. Grier J.T., Forbes L.R., Monaco-Shawver L., Oshinsky J., Atkinson T.P., Moody C., et al. Human immunodeficiency-causing mutation defines CD16 in spontaneous NK cell cytotoxicity. J Clin Invest 2012, 122:3769-3770.
157. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-760.
158. Kastbom A., Ahmadi A., Soderkvist P., Skogh T. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project). Rheumatology (Oxford) 2005, 44:1294-1300.
159. Hafler J.P., Maier L.M., Cooper J.D., Plagnol V., Hinks A., Simmonds M.J., et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009, 10:5-10.
160. Suzuki A., Yamada R., Kochi Y., Sawada T., Okada Y., Matsuda K., et al. Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. Nat Genet 2008, 40:1224-1230.
161. Rusakiewicz S., Nocturne G., Lazure T., Semeraro M., Flament C., Caillat-Zucman S., et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med 2013, 5:195ra196.
162. Melum E., Karlsen T.H., Schrumpf E., Bergquist A., Thorsby E., Boberg K.M., et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008, 47:90-96.
163. Van Belle T.L., von Herrath M.G. The role of the activating receptor NKG2D in autoimmunity. Mol Immunol 2009, 47:8-11.
164. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., Shimomura Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-120.
165. Guerra N., Pestal K., Juarez T., Beck J., Tkach K., Wang L., et al. A selective role of NKG2D in inflammatory and autoimmune diseases. Clin Immunol 2013, 149:432-440.
166. Mingari M.C., Pietra G., Moretta L. Human cytolytic T lymphocytes expressing HLA class-I-specific inhibitory receptors. Curr Opin Immunol 2005, 17:312-320.
167. Kulkarni S., Martin M.P., Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008, 20:343-350.
168. Xiong S., Sharkey A.M., Kennedy P.R., Gardner L., Farrell L.E., Chazara O., et al. Maternal uterine NK cell-activating receptor KIR2DS1 enhances placentation. J Clin Invest 2013, 123:4264-4270.
169. Momot T., Koch S., Hunzelmann N., Krieg T., Ulbricht K., Schmidt R.E., et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004, 50:1561-1570.
170. Nelson G.W., Martin M.P., Gladman D., Wade J., Trowsdale J., Carrington M. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004, 173:4273-4280.
171. Yen J.H., Moore B.E., Nakajima T., Scholl D., Schaid D.J., Weyand C.M., et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001, 193:1159-1160.
172. Mehers K.L., Long A.E., van der Slik A.R., Aitken R.J., Nathwani V., Wong F.S., et al. An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia 2011, 54:3062-3070.
173. Furukawa H., Murata S., Yabe T., Shimbara N., Keicho N., Kashiwase K., et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999, 103:755-760.
174. de la Salle H., Hanau D., Fricker D., Urlacher A., Kelly A., Salamero J., et al. Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science 1994, 265:237-240.
175. Cerundolo V., de la Salle H. Description of HLA class I- and CD8-deficient patients: insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Semin Immunol 2006, 18:330-340.
176. Furukawa H., Yabe T., Watanabe K., Miyamoto R., Miki A., Akaza T., et al. Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). Hum Immunol 1999, 60:32-40.
177. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006, 25:331-340.
178. Rieux-Laucat F., Hivroz C., Lim A., Mateo V., Pellier I., Selz F., et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N Engl J Med 2006, 354:1913-1920.
179. Roberts J.L., Lauritsen J.P., Cooney M., Parrott R.E., Sajaroff E.O., Win C.M., et al. T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood 2007, 109:3198-3200.
180. Paloneva J., Kestila M., Wu J., Salminen A., Bohling T., Ruotsalainen V., et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000, 25:357-360.
181. 2+ revealed by human T-cell immunodeficiency. Nature 2011, 475:471-480.
182. 2+ regulates cytotoxic functions of NK and CD8T cells in chronic EBV infection through NKG2D. Science 2013, 341:186-190.
183. Nichols K.E., Harkin D.P., Levitz S., Krainer M., Kolquist K.A., Genovese C., et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A 1998, 95:13765-13770.
184. Coffey A.J., Brooksbank R.A., Brandau O., Oohashi T., Howell G.R., Bye J.M., et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129-130.
185. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462-470.
186. Arico M., Imashuku S., Clementi R., Hibi S., Teramura T., Danesino C., et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood 2001, 97:1131-1140.
187. Cannons J.L., Tangye S.G., Schwartzberg P.L. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 2011, 29:665-670.
188. Tangye S.G., Phillips J.H., Lanier L.L., Nichols K.E. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol 2000, 165:2932-2940.
189. Parolini S., Bottino C., Falco M., Augugliaro R., Giliani S., Franceschini R., et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000, 192:337-340.
190. Huck K., Feyen O., Niehues T., Ruschendorf F., Hubner N., Laws H.J., et al. Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009, 119:1350-1360.
191. Mansouri D., Mahdaviani S.A., Khalilzadeh S., Mohajerani S.A., Hasanzad M., Sadr S., et al. IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection. Int Arch Allergy Immunol 2012, 158:418-420.
192. Khurana D., Arneson L.N., Schoon R.A., Dick C.J., Leibson P.J. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol 2007, 178:3575-3580.
193. Kuehn H.S., Niemela J.E., Rangel-Santos A., Zhang M., Pittaluga S., Stoddard J.L., et al. Loss-of-function of the protein kinase C delta (PKCdelta) causes a B-cell lymphoproliferative syndrome in humans. Blood 2013, 121:3117-3120.
194. Rigaud S., Fondaneche M.C., Lambert N., Pasquier B., Mateo V., Soulas P., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 2006, 444:110-120.
195. Marsh R.A., Madden L., Kitchen B.J., Mody R., McClimon B., Jordan M.B., et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010.
196. Speckmann C., Lehmberg K., Albert M.H., Damgaard R.B., Fritsch M., Gyrd-Hansen M., et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol 2013, 149:133-140.
197. Bryceson Y.T., Pende D., Maul-Pavicic A., Gilmour K.C., Ufheil H., Vraetz T., et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood 2012, 119:2754-2760.
198. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994, 79. [following 922].
199. Lanzi G., Moratto D., Vairo D., Masneri S., Delmonte O., Paganini T., et al. A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. J Exp Med 2012, 209:29-34.
200. Gismondi A., Cifaldi L., Mazza C., Giliani S., Parolini S., Morrone S., et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 2004, 104:436-440.
201. Orange J.S., Ramesh N., Remold-O'Donnell E., Sasahara Y., Koopman L., Byrne M., et al. Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 2002, 99:11351-11360.
202. Stabile H., Carlino C., Mazza C., Giliani S., Morrone S., Notarangelo L.D., et al. Impaired NK-cell migration in WAS/XLT patients: role of Cdc42/WASp pathway in the control of chemokine-induced beta2 integrin high-affinity state. Blood 2010, 115:2818-2820.
203. Ombrello M.J., Remmers E.F., Sun G., Freeman A.F., Datta S., Torabi-Parizi P., et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N Engl J Med 2012, 366:330-340.
204. 2+ entry in the immune system and beyond. Immunol Rev 2009, 231:189-190.
205. Maul-Pavicic A., Chiang S.C.C., Rensing-Ehl A., Jessen B., Fauriat C., Wood S.M., et al. ORAI1-mediated calcium influx is required for human cytotoxic lymphocyte degranulation and target cell lysis. Proc Natl Acad Sci U S A 2011.
206. de Saint Basile G., Menasche G., Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 2010, 10:568-570.
207. Menasche G., Pastural E., Feldmann J., Certain S., Ersoy F., Dupuis S., et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 2000, 25:173-180.
208. Barbosa M.D., Nguyen Q.A., Tchernev V.T., Ashley J.A., Detter J.C., Blaydes S.M., et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996, 382:262-270.
209. Wood S.M., Meeths M., Chiang S.C., Bechensteen A.G., Boelens J.J., Heilmann C., et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood 2009, 114:4117-4120.
210. Roder J.C., Haliotis T., Klein M., Korec S., Jett J.R., Ortaldo J., et al. A new immunodeficiency disorder in humans involving NK cells. Nature 1980, 284:553-560.
211. Bryceson Y.T., Rudd E., Zheng C., Edner J., Ma D., Wood S.M., et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 2007, 110:1906-1910.
212. Sepulveda F.E., Debeurme F., Menasche G., Kurowska M., Cote M., Pachlopnik Schmid J., et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood 2013, 121:595-600.
213. Hackmann Y., Graham S.C., Ehl S., Honing S., Lehmberg K., Arico M., et al. Syntaxin binding mechanism and disease-causing mutations in Munc18-2. Proc Natl Acad Sci U S A 2013, 110:E4482-E4490.
214. Su H., Bidere N., Zheng L., Cubre A., Sakai K., Dale J., et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005, 307:1465-1470.
215. Zonana J., Elder M.E., Schneider L.C., Orlow S.J., Moss C., Golabi M., et al. A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). Am J Hum Genet 2000, 67:1555-1560.
216. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001, 27:277-280.
217. Orange J.S., Brodeur S.R., Jain A., Bonilla F.A., Schneider L.C., Kretschmer R., et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002, 109:1501-1510.
218. Bogunovic D., Byun M., Durfee L.A., Abhyankar A., Sanal O., Mansouri D., et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 2012, 337:1684-1690.
219. Al-Muhsen S., Casanova J.L. The genetic heterogeneity of Mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008, 122:1043-1050. [quiz 1052-1043].
220. Fu W., Ergun A., Lu T., Hill J.A., Haxhinasto S., Fassett M.S., et al. A multiply redundant genetic switch 'locks in' the transcriptional signature of regulatory T cells. Nat Immunol 2012, 13:972-980.
221. Nowak M.A., Boerlijst M.C., Cooke J., Smith J.M. Evolution of genetic redundancy. Nature 1997, 388:167-170.
222. Kafri R., Springer M., Pilpel Y. Genetic redundancy: new tricks for old genes. Cell 2009, 136:389-390.